Monika Długosz-Danecka

Professor

Maria Sklodowska-Curie National Research Institute of Oncology

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Grzegorz Władysław Basak

University Clinical Centre

POLAND

View details

Krzysztof Giannopoulos

Medical University of Lublin

POLAND

View details

Przemyslaw Biecek

University of Warsaw

POLAND

View details

Joanna Drozd-Sokołowska

Medical University of Warsaw

POLAND

View details

Pawel Steckiewicz

Jan Kochanowski University

POLAND

View details

Paolo Ghia

ITALY

View details

Joanna Barankiewicz

Instytut Hematologii i Transfuzjologii

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Monika Długosz-Danecka

Research Interests

Explore related searches

Contact this professor

Articles (10)

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia—A Multicenter Report by the Polish Lymphoma Research Group

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.

Rituximab biosimilars in clinical practice.

Collaborators (7)

Grzegorz Władysław Basak

Krzysztof Giannopoulos

Przemyslaw Biecek

Joanna Drozd-Sokołowska

Pawel Steckiewicz

Paolo Ghia

Joanna Barankiewicz

Make your next move.